At Fate, we are pioneering research into stem cell biology and creating a portfolio of first-in-class pharmacologic modulators of stem cells targeting diseases with high unmet need. Fate currently has six active therapeutic development efforts underway:
Product
Therapeutic Area
Target Indication
Research
Preclinical
Phase I
Phase II
Phase III
Registration
Marketed
Ex Vivo Stem Cell Modulation
ProHema
Hematology
Hematological Malignacy
eHSCs
Ischemia
Ischemic Disease
In Vivo Biological Therapeutics
FT101
Cardiac / Ischemic
Myocardial Infarction
FT201
Metabolic
Type 1 Diabetes
FT301
Musculoskeletal
Muscular Atrophies / Dystrophies
In Situ Small Molecule Stem Cell Modulators
CNS
Hearing
Restoration
Restoration